Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1R) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice

Journal of Neuroscience

Volumn 34, Issue 15, 2014, Pages 5152-5163

  Morgan, Daniel J ^a   Davis, Brian J ^a   Kearn, Chris S ^b   Marcus, David ^a   Cook, Alex J ^a   Wager Miller, Jim ^a   Straiker, Alex ^a   Myoga, Michael H ^b   Karduck, Jeffrey ^a   Leishman, Emma ^a   Sim Selley, Laura J ^c   Czyzyk, Traci A ^a,d   Bradshaw, Heather B ^a   Selley, Dana E ^c   Mackie, Ken ^a  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Cannabinoid; CB1; Desensitization; GPCR; THC; Tolerance

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; DRONABINOL; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 6; RETINA S ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; DOWN REGULATION; DRUG DEPENDENCE; DRUG HYPERSENSITIVITY; DRUG TOLERANCE; ELECTROPHYSIOLOGY; GENOTYPE; MALE; MASS SPECTROMETRY; MOUSE; MUTATION; NONHUMAN; OPEN FIELD TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SOUTHERN BLOTTING; TAIL FLICK TEST; UPREGULATION; WESTERN BLOTTING;

CANNABINOID; CB1; DESENSITIZATION; GPCR; THC; TOLERANCE;

AMINO ACID MOTIFS; ANIMALS; CANNABINOID RECEPTOR AGONISTS; CENTRAL NERVOUS SYSTEM SENSITIZATION; DRONABINOL; DRUG TOLERANCE; G-PROTEIN-COUPLED RECEPTOR KINASES; HIPPOCAMPUS; MEMBRANE POTENTIALS; MICE; MUTATION, MISSENSE; NEURONS; PERIAQUEDUCTAL GRAY; PHOSPHORYLATION; PROTEIN BINDING; RECEPTOR, CANNABINOID, CB1; SPINAL CORD;

EID: 84899489705     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3445-12.2014     Document Type: Article

References (36)

1. Bedi G, Foltin RW, Gunderson EW, Rabkin J, Hart CL, Comer SD, Vosburg SK, Haney M (2010) Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology (Berl) 212:675-686. CrossRef Medline
2. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-2498. CrossRef Medline
3. Bradshaw HB, Rimmerman N, Krey JF, Walker JM (2006) Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am J Physiol Regul Integr Comp Physiol 291:R349-R358. CrossRef Medline
4. Breivogel CS, Lambert JM, Gerfin S, Huffman JW, Razdan RK (2008) Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in betaarrestin2 -/- mice. Behav Pharmacol 19:298-307. CrossRef Medline
5. Cook SA, Lowe JA, Martin BR (1998) CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150-1156.Medline
6. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87. CrossRef Medline
7. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (2001) Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 98:9371-9376. CrossRef Medline
8. Daigle TL, Kwok ML, Mackie K (2008a) Regulation of CB1 cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism. J Neurochem 106:70-82. CrossRef Medline
9. Daigle TL, Kearn CS, Mackie K (2008b) Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology 54:36-44. CrossRef Medline
10. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510. CrossRef Medline
11. D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J (2008) Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33:2505-2516. CrossRef Medline
12. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352-358. CrossRef Medline
13. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27:107-144. CrossRef Medline
14. Hsieh C, Brown S, Derleth C, Mackie K (1999) Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73:493-501. CrossRef Medline
15. Jin W, Brown S, Roche JP, Hsieh C, Celver JP, Kovoor A, Chavkin C, Mackie K (1999) Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 19:3773-3780.Medline
16. Koob GF (2009) Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56 [Suppl 1]:18-31. CrossRef Medline
17. Kouznetsova M, Kelley B, Shen M, Thayer SA (2002) Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Mol Pharmacol 61:477-485. CrossRef Medline
18. Lichtman AH, Martin BR (1991) Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 258:517-523.Medline
19. Lichtman AH, Cook SA, Martin BR (1996) Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276:585-593.Medline
20. Lichtman AH, Sheikh SM, Loh HH, Martin BR (2001) Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)- tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther 298:1007-1014.Medline
21. Martin BR, Sim-Selley LJ, Selley DE (2004) Signaling pathways involved in the development of cannabinoid tolerance. Trends Pharmacol Sci 25: 325-330. CrossRef Medline
22. Martini L, Thompson D, Kharazia V, Whistler JL (2010) Differential regulation of behavioral tolerance to WIN55,212-2 by GASP1. Neuropsychopharmacology 35:1363-1373. CrossRef Medline
23. McKinney DL, Cassidy MP, Collier LM, Martin BR, Wiley JL, Selley DE, Sim-Selley LJ (2008) Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 324:664-673. CrossRef Medline
24. Melis M, Pillolla G, Luchicchi A, Muntoni AL, Yasar S, Goldberg SR, Pistis M (2008) Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 28:13985-13994. CrossRef Medline
25. Moore CA, Milano SK, Benovic JL (2007) Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69:451-482. CrossRef Medline
26. Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, Sim-Selley LJ (2012) beta-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol Psychiatry 71:714-724. CrossRef Medline
27. Nyíri G, Cserép C, Szabadits E, Mackie K, Freund TF (2005) CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136:811-822. CrossRef Medline
28. Rawls SM, Cabassa J, Geller EB, Adler MW (2002) CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2- methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrr olo[3,2,1ij]quinolin-6-one]-induced hypothermia. J Pharmacol Exp Ther 301:963-968. CrossRef Medline
29. Schlosburg JE, Carlson BL, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, Lichtman AH (2009) Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J 11:342-352. CrossRef Medline
30. Sim-Selley LJ (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15:91-119. CrossRef Medline
31. Straiker A, Mackie K (2005) Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569:501-517. CrossRef Medline
32. Straiker A, Hu SS, Long JZ, Arnold A, Wager-Miller J, Cravatt BF, Mackie K (2009) Monoacylglycerol lipase limits the duration of endocannabinoidmediated depolarization-induced suppression of excitation in autaptic hippocampal neurons. Mol Pharmacol 76:1220-1227. CrossRef Medline
33. Straiker A, Wager-Miller J, Hu SS, Blankman JL, Cravatt BF, Mackie K (2011) COX-2 and fatty acid amide hydrolase can regulate the time course of depolarization-induced suppression of excitation. Br J Pharmacol 164:1672-1683. CrossRef Medline
34. Straiker A, Wager-Miller J, Mackie K (2012) The CB1 cannabinoid receptor C-terminus regulates receptor desensitization in autaptic hippocampal neurones. Br J Pharmacol 165:2652-2659. CrossRef Medline
35. Tsou K, Patrick SL, Walker JM (1995) Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 280:R13-R15. CrossRef Medline
36. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sørgård M, Di Marzo V, Julius D, Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457. CrossRef Medline